Review
Medicine, Research & Experimental
Karim Chouchane, Giovanni Di Zenzo, Dario Pitocco, Laura Calabrese, Clara De Simone
Summary: Bullous pemphigoid (BP) is a common autoimmune skin disease that primarily affects patients over 60 years old. While conventional and DPP-4i-associated BP are thought to share similar clinical and histopathological features, recent literature shows that these two forms are quite distinct.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Medicine, Research & Experimental
Milene T. Fontes, Daniel F. Arruda-Junior, Danubia Silva dos Santos, Joao Carlos Ribeiro-Silva, Edinei L. Anto, Paulo F. J. Tucci, Luciana V. Rossoni, Adriana C. C. Girardi
Summary: This study tested the effects of DPP4 inhibitor vildagliptin on aortic hyperreactivity in male HF rats. The results showed that DPP4i mitigated the hypercontractility of HF aortas and enhanced NO bioavailability, suggesting a potential protective effect on the arteries.
Article
Medicine, Research & Experimental
Daniel F. Arruda-Junior, Thiago A. Salles, Flavia L. Martins, Ednei L. Antonio, Paulo J. F. Tucci, Luis Henrique W. Gowdak, Caio A. M. Tavares, Adriana C. Girardi
Summary: This study found that there is an interaction between DPP4 and RAS in heart failure rats, and combined inhibition of DPP4 and RAS may not provide additional cardioprotection compared to monotherapy.
Article
Endocrinology & Metabolism
Oliver Kuss, Marie Elisabeth Opitz, Lea Verena Brandstetter, Sabrina Schlesinger, Michael Roden, Annika Hoyer
Summary: Treatment heterogeneity and identification of clinical predictors are prerequisites for the application of precision medicine. This study utilized meta-regression analysis on placebo-controlled randomized trials of type 2 diabetes treatment and found that there is an increase in the variability of glycaemic control after treatment, with GLP-1 receptor agonists showing the most pronounced effect.
Review
Endocrinology & Metabolism
Oyepeju Ogundipe, Mohsen Mazidi, Ken Lee Chin, Deval Gor, Andrew McGovern, Berhe W. Sahle, Gyorgy Jermendy, Maarit Jaana Korhonen, Bernard Appiah, Zanfina Ademi, Marie Louise De Bruin, Danny Liew, Richard Ofori-Asenso
Summary: Adherence to and persistence with DPP4 inhibitors among patients with type 2 diabetes mellitus is suboptimal but consistent across medications within the class. In-class switching is rare, with saxagliptin and alogliptin being the most commonly switched DPP4 inhibitors. Interventions to improve treatment adherence and persistence for this patient population may be needed.
ACTA DIABETOLOGICA
(2021)
Review
Food Science & Technology
Carina Proenca, Daniela Ribeiro, Marisa Freitas, Felix Carvalho, Eduarda Fernandes
Summary: Type 2 diabetes is a growing global health problem caused by insulin secretion defects and/or insulin resistance. The role of protein tyrosine phosphatase 1B and dipeptidyl peptidase-4 in T2D has attracted scientific attention, with a focus on the potential of flavonoids as therapeutic agents. Studies have explored the inhibitory effects of flavonoids on PTP1B and DPP-4 activities, aiming to discover compounds with improved potential for treating T2D.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
(2022)
Article
Food Science & Technology
Wei Wang, Xiaoqing Liu, Yiju Li, Haixi You, Zhipeng Yu, Liying Wang, Xuebo Liu, Long Ding
Summary: In this study, different enzymes and simulated digestion were used to investigate the DPP-IV inhibitory activities of oat protein hydrolysates. Neutrase was found to produce oat protein hydrolysate with the most potent DPP-IV inhibitory property, and ten new DPP-IV inhibitory peptides were identified. Molecular docking experiments further confirmed the interaction between these peptides and DPP-IV. Therefore, oat could be a promising source of dietary supplement for type 2 diabetes mellitus (T2DM).
Article
Food Science & Technology
Juan Wang, Yujia Xie, Yuanyuan Luan, Tingting Guo, Shanshan Xiao, Xingxing Zeng, Shaohui Zhang
Summary: The objective of this study was to isolate and identify intracellular bioactive peptides from mouse lymphocytes before and after lipopolysaccharide (LPS) stimulation. A total of 131 novel peptides were discovered, and their bioactivity and function were predicted. Two peptides with better inhibition activity were verified.
FOOD SCIENCE AND HUMAN WELLNESS
(2022)
Article
Endocrinology & Metabolism
Yukari Kobayashi, Jin Long, Shozen Dan, Neil M. Johannsen, Ruth Talamoa, Sonia Raghuram, Sukyung Chung, Kyla Kent, Marina Basina, Cynthia Lamendola, Francois Haddad, Mary B. Leonard, Timothy S. Church, Latha Palaniappan
Summary: This study aimed to investigate the optimal exercise regimen for individuals with "normalweight type 2 diabetes" (BMI < 25 kg/m²). The results showed that strength training alone significantly reduced HbA1c levels and increased lean mass, and strength training was superior to aerobic training alone or combination training.
Article
Immunology
Zhicheng Zheng, Peiyu Liang, Baohua Hou, Xin Lu, Qianwen Ma, Xiaomin Yu, Song Han, Biwen Peng, Taoxiang Chen, Wanhong Liu, Jun Yin, Xiaohua He
Summary: The study revealed that DPP4 is involved in DAM conversion and epilepsy, and treatment with DPP4 inhibitor sitagliptin can alleviate epilepsy and promote DAM phenotypic transformation, resulting in enhanced morphological features and functions of microglia.
JOURNAL OF NEUROINFLAMMATION
(2021)
Article
Endocrinology & Metabolism
Vaia Lambadiari, Aikaterini Kountouri, Foteini Kousathana, Emmanouil Korakas, Georgios Kokkalis, Sofia Theotokoglou, Lina Palaiodimou, Pelagia Katsimbri, Ignatios Ikonomidis, Konstantinos Theodoropoulos, Evangelia Papadavid
Summary: The study showed that treatment with dipeptidyl-peptidase 4 inhibitors, especially vildagliptin, is significantly associated with an increased risk of bullous pemphigoid development.
BMC ENDOCRINE DISORDERS
(2021)
Article
Chemistry, Physical
Jaya P. Ambhore, Purushottam R. Laddha, Anjali Nandedkar, Prashant V. Ajmire, Deshraj S. Chumbhale, Ashish B. Navghare, Vitthal G. Kuchake, Prashant J. Chaudhari, Vaibhav S. Adhao
Summary: Nowadays, Dipeptidyl peptidase-IV (DPP-IV) has emerged as a promising drug target for the treatment of Type 2 diabetes mellitus (T2DM). Currently available DPP-IV inhibitors effectively lower blood glucose levels in T2DM patients without causing common side effects such as hypoglycemia, weight gain, and gastrointestinal disturbances. This review focuses on the molecular insights, recent developments in design and discovery, and structure-activity relationships of potential DPP-IV inhibitors.
JOURNAL OF MOLECULAR STRUCTURE
(2023)
Review
Endocrinology & Metabolism
Ayan Roy, Jayaprakash Sahoo, Niya Narayanan, Chandhana Merugu, Sadishkumar Kamalanathan, Dukhabandhu Naik
Summary: DPP-4 inhibitors play a crucial role in managing type 2 diabetes, but their relationship with autoimmune diseases is complex. Further research is needed to understand the impact of DPP-4 inhibition on the immune system.
WORLD JOURNAL OF DIABETES
(2021)
Article
Multidisciplinary Sciences
Armieti Babaiedarzi, Saba Ghanbari, Maryam Mehrad Seresht, Modara Nasiri
Summary: This study investigated the therapeutic effects of Scrophularia striata in controlling diabetic injury and pancreatic complications caused by diabetes. The results showed that S. striata could normalize the factors related to diabetes, increase the expression of Pdx1 and Ins1 genes, and improve the complications of diabetes.
SCIENTIFIC REPORTS
(2022)
Article
Food Science & Technology
Haixi You, Yu Zhang, Tianliang Wu, Juanrui Li, Liying Wang, Zhipeng Yu, Jingbo Liu, Xuebo Liu, Long Ding
Summary: This study aimed to investigate the DPP-IV inhibitory peptides from rapeseed proteins. The results showed that rapeseed protein hydrolysates had DPP-IV inhibitory activities. In silico approach was used to select potential DPP-IV inhibitory peptides and 12 of them were determined to have inhibitory activities. Four peptides (IPK, LPR, VPHL, and IPNQT) were identified from rapeseed protein hydrolysate, with IPK exhibiting the highest inhibitory activity. IPK acted as a competitive inhibitor and interacted with specific residues in the S1 and S2 pockets of DPP-IV. These findings suggest that rapeseed proteins are a valuable source of DPP-IV inhibitory peptides for the management of type 2 diabetes.
LWT-FOOD SCIENCE AND TECHNOLOGY
(2022)
